Elanco Animal Health is seeing strong growth in its U.S. pet health business, driven by innovative products that protect pets year-round against ticks and allergies. Changing climate patterns have extended tick and pollen seasons, increasing demand for parasiticides and dermatology treatments. Elanco's market share and pricing power are rising as it meets pet owners' evolving needs through an omnichannel approach. The company expects continued growth and price gains in the second half of 2026, supported by new product launches and increased compliance via home delivery programs.
Elanco Animal Health's momentum in pet health innovation coincides with a mixed day for health-sector stocks on Pluang. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 15, 2026 16:41 WIB: of 91 priced US health-sector stocks, 35 rose and 48 fell. Notable movers include INO (Inovio Pharmaceuticals Inc) at USD 1.21, up 2.54%, ABCL (AbCellera Biologics Inc) at USD 11.00, down 1.52%, and HRTX (Heron Therapeutics Inc) at USD 0.32, up 1.49%.
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG at €39 per share in cash, representing a significant premium over recent prices. The acquisition aims to strengthen Red Cat's Blue Ops u...
The VanEck Semiconductor ETF (SMH) dropped nearly 10% due to a rotation of capital from AI and tech stocks into sectors like Financials and Energy amid worsening liquidity and macroeconomic challenges. The portfolio manager reduced cash holdings from...
Telix Pharmaceuticals and Ekalia have teamed up to establish U.S.-based production of astatine-211, a rare alpha-emitting isotope used in targeted alpha therapy for cancer. This collaboration combines IBA's cyclotron technology, Framatome's nuclear e...
Ekalia, a joint venture between IBA and Framatome, has partnered with Telix Pharmaceuticals to accelerate the production of Astatine-211, a promising alpha-emitting radioisotope used in targeted cancer therapies, in the United States. The collaborati...
